Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Volatility & Risk
Vivos Therapeutics has a beta of 6.1, indicating that its share price is 510% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Earnings & Valuation
This table compares Vivos Therapeutics and Lyra Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.35 | -$21.17 million | ($2.14) | -0.21 |
| Lyra Therapeutics | $600,000.00 | 1.72 | -$93.43 million | ($19.15) | -0.03 |
Vivos Therapeutics has higher revenue and earnings than Lyra Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Vivos Therapeutics and Lyra Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Lyra Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 534.35%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Lyra Therapeutics.
Institutional & Insider Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Vivos Therapeutics and Lyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
| Lyra Therapeutics | -5,491.17% | -1,010.91% | -58.92% |
Summary
Vivos Therapeutics beats Lyra Therapeutics on 8 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
